Sign In
Buy QTTB
$11.88
-0.770 (-6.09%)
At Close: Jun 23, 2026
Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata
06:59am, Wednesday, 30'th Apr 2025
WALTHAM, Mass. , April 30, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and
-- SIGNAL-AA Part B topline data readout on-track for 1H'26 -- WALTHAM, Mass. , April 16, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio" or the "Company"), a clinical stage biotechnolog
All You Need to Know About Q32 Bio (QTTB) Rating Upgrade to Buy
01:01pm, Tuesday, 08'th Apr 2025
Q32 Bio (QTTB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update
06:59am, Tuesday, 11'th Mar 2025
-- Presented bempikibart SIGNAL-AA Phase 2a Part A alopecia areata (AA) data demonstrating encouraging clinical activity and highlighting the potential to be a differentiated treatment as a late-break
-- Results presented in AAD late-breaker demonstrate bempikibart's encouraging improvement on SALT reduction at week 24 and continued effects after dosing cessation in patients with severe and very se
-- Oral presentation to highlight Phase 2a Part A results of the randomized, placebo-controlled SIGNAL-AA clinical trial evaluating bempikibart in patients with severe and very severe alopecia areata
Q32 Bio to Participate in Upcoming March Investor Conferences
06:59am, Wednesday, 26'th Feb 2025
WALTHAM, Mass. , Feb. 26, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis
Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata
04:05pm, Monday, 10'th Feb 2025
-- Based on continued emergence of bempikibart data from SIGNAL-AA Part A, including strong re-consent rates and patient demand for continued dosing, Company initiating open-label extension in 1H'25;
Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference
04:05pm, Tuesday, 04'th Feb 2025
WALTHAM, Mass. , Feb. 4, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis,
Q32 Bio (QTTB) Upgraded to Buy: What Does It Mean for the Stock?
01:16pm, Tuesday, 07'th Jan 2025
Q32 Bio (QTTB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's Why Q32 Bio Stock Hit a New Record Low on Wednesday
12:01pm, Thursday, 12'th Dec 2024
Shares of QTTB fall after its experimental autoimmune disease drug failed to meet the primary endpoint in a mid-stage study for eczema.
Why Is Skin Disease-Focused Q32 Bio Stock Trading Lower On Wednesday?
11:32am, Wednesday, 11'th Dec 2024
On Wednesday, Q32 Bio Inc. QTTB revealed topline results from the SIGNAL-AA Phase 2a signal finding trial evaluating bempikibart (ADX-914) for alopecia areata (AA).
Q32 Bio Crashes 67% On A 'Messy' Update In Eczema, Alopecia Treatment
09:42am, Wednesday, 11'th Dec 2024
Q32 Bio delivered a "messy" update for its eczema and alopecia treatment, leading the biotech stock to collapse to a record low. The post Q32 Bio Crashes 67% On A 'Messy' Update In Eczema, Alopecia Tr
Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program
04:05pm, Tuesday, 10'th Dec 2024
-- SIGNAL-AA demonstrated encouraging clinical activity of bempikibart in patients with alopecia areata (AA), including improvement from baseline on SALT score and meaningful achievement of SALT-20 r
Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update
06:59am, Thursday, 07'th Nov 2024
-- Bempikibart Phase 2 topline results in atopic dermatitis (AD) and alopecia areata (AA) remain on-track for Q4'24, with topline data from both trials expected in December -- -- Enrollment ongoing in
